Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
Executive Summary
CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.
You may also be interested in...
Affini-T Raises $175m For Bicoastal TCR Play Focused On KRAS-Mutated Solid Tumors
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.
Entasis Anticipates First FDA Approval Of Pathogen-Specific Antibacterial
With Phase III data showing non-inferiority to colistin, as well as nephrotoxicity superiority, Entasis thinks sulbactam/durlobactam will provide a new standard of care and succeed where Achaogen’s Zemdri failed.
Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.